• Home
  • About APS
  • APS News
  • Job Postings and Ads
  • Events and Education
  • Goverment Affairs
  • 2024 Annual Meeting
  • Education-OUD
  • Education-On Demand
  • Mental Health Resources

To Buy Augmentin Online Visit Our Pharmacy ↓

Click HERE To Buy Augmentin Online ↓




  • Augmentin Vs. Other Antibiotics: Key Differences Explained

    Understanding Augmentin: Composition and Mechanism of Action


    Augmentin is a unique antibiotic composed of amoxicillin and clavulanate potassium. Amoxicillin, a penicillin-derived antibiotic, disrupts bacterial cell wall synthesis, leading to cell death. Clavulanate acts to inhibit beta-lactamases, enzymes that some bacteria produce to resist antibiotics. This combination broadens Augmentin’s efficacy, making it capable of tackling both beta-lactamase-producing and non-producing organisms. The synergistic action not only targets common strains but also curtails bacterial resistance, elevating Augmentin above many standard antibiotics. Understanding this dynamic helps in selecting the appropriate antibiotic treatment.

    Component Function
    Amoxicillin Disrupts bacterial cell wall synthesis
    Clavulanate Inhibits beta-lactamases to prevent resistance



    Spectrum of Activity: Augmentin's Broad Vs. Targeted Impact



    Augmentin stands out due to its composition—a powerful combination of amoxicillin and clavulanate potassium. This blend bestows it with a broad-spectrum impact, allowing it to combat a wide array of bacteria, including those that are resistant to amoxicillin alone. The clavulanate component plays a crucial role by inhibiting beta-lactamase enzymes, which many bacteria produce to resist antibiotics.

    In contrast, more targeted antibiotics may focus on specific types of bacteria, leading to higher effectiveness in select cases. However, this targeting can limit their applicability when infections involve multiple or resistant bacteria. Thus, Augmentin’s broad-spectrum nature offers versatility, making it a preferred option in mixed bacterial infections.



    Bacterial Resistance: Challenges in Augmentin Vs. Others


    Augmentin, a potent antibiotic, combines amoxicillin with clavulanic acid to combat resistant bacteria. While this formulation enhances its effectiveness against beta-lactamase producing bacteria, it doesn't exempt it from challenges. Bacterial resistance is an evolving adversary, with certain strains developing mechanisms to evade even the advanced action of Augmentin.

    Other antibiotics face similar hurdles, but resistance levels can vary significantly. Factors such as the misuse or overuse of antibiotics often exacerbate resistance issues. Augmentin’s dual-action approach attempts to mitigate resistance, yet the battle against resistant pathogens requires ongoing vigilance and innovation.



    Side Effects: Comparing Augmentin to Common Alternatives



    Augmentin, a popular antibiotic, often raises questions about its side effects compared to other common antibiotics. One notable aspect is its potential to cause gastrointestinal disturbances, such as diarrhea and nausea, which stem from its clavulanic acid component. While these are generally mild, they can be bothersome for some patients. On the other hand, antibiotics like ciprofloxacin might present risks relating to tendon damage, especially in older adults, and penicillin-based options may trigger allergic reactions.

    Additionally, Augmentin's use can sometimes lead to yeast infections due to its broad-spectrum activity disrupting normal flora. This breadth is also seen in alternatives like doxycycline, albeit with less gastrointestinal impact. Nevertheless, all antibiotics carry a risk of disrupting natural microbiomes, so individual response and medical history are paramount when considering side effects.



    Usage Scenarios: When to Prescribe Augmentin over Others


    In the bustling world of antibiotics, Augmentin emerges as a versatile player. Its combination of amoxicillin and clavulanate makes it particularly effective against bacteria that commonly produce beta-lactamase, an enzyme that can render other antibiotics useless. This unique formulation is particularly advantageous in treating mixed infections where both aerobic and anaerobic pathogens are present, such as in cases of sinusitis, skin infections, or urinary tract infections.

    Sensing when to wield Augmentin requires a keen understanding of the infection's nature. Physicians often choose Augmentin when they suspect or know the presence of resistant bacteria, especially in community-acquired infections. It’s the go-to choice when empirical treatment calls for something more robust than standard antibiotics like amoxicillin alone.

    However, Augmentin isn't always the first-line treatment.

    Condition Antibiotic Choice Rationale
    Sinusitis Augmentin Effective against resistant bacteria
    Skin Infections Augmentin Targets mixed infections
    Simple Infections Other Antibiotics Cost and resistance considerations

    Cost, availability, and patient history might lead prescribers to opt for alternatives that are more narrowly targeted. In situations where a narrower spectrum antibiotic suffices and cost is a concern, others may be preferred.



    Cost Considerations: Augmentin Pricing and Availability


    When it comes to antibiotics, understanding the costs can significantly influence both decision-making and accessibility, particularly with Augmentin. While known for its effectiveness in tackling resistant bacterial strains, Augmentin can be priced higher compared to its alternatives due to its unique combination of amoxicillin and clavulanate potassium. Availability may vary depending on geographical location and healthcare provider policies, impacting how often it is prescribed. Patients and healthcare professionals often weigh these financial aspects alongside clinical benefits to make informed treatment choices. The nuances of insurance coverage also play a pivotal role, influencing patient out-of-pocket expenses and overall availability.





ARIZONA PSYCHIATRIC SOCIETY 2024-2025 EXECUTIVE Board

President: Nicholas Ahrendt, MD President-Elect: Margaret Balfour, MD, PhDVice President: Brenner Freeman, MDTreasurer: Robert Rymowicz, DOSecretary: Chiranjir "Ravi" Narine, MD Co Resident-Fellow Member Representatives: Nehal Samra, MD Creighton Matthew Mitchell, MD UA-PhoenixGagan Singh, MD UA-Tucson
APA Assembly Representatives: Jason Curry, DO (serves term concluding 2024) Jasleen Chhatwal, MBBS, MD (two-year term concluding 2024)Payam Sadr, MD (one-year term concluding 2024) Past President Gagandeep Singh, MD, DFAPA Stephen "Larry" Mecham, DO The Society thanks these members for their leadership.

Celebrating our members

Chase was born and raised in Phoenix, AZ, and attended ASU for a bachelor’s degree in business then attended KCUMB for medical school in Kansas City. He was excited to return home to AZ when he found out he'd been matched with UACOM – Phoenix for his psychiatry residency.
He was first drawn to the field of psychiatry during his years in medical school as he found the psychiatric subject matter and the patients to be the most engaging and interesting of all his studies. He quickly came to realize that without a healthy mind, one is unable to thoroughly experience life constructive way. He wanted to be the person to help those struggling with mental illness as he found these cases and experiences to be the most rewarding in medicine.
Dr. Crookham said he has been lucky enough to have been matched at a great psychiatric residency program where he gets to learn from great mentors and colleagues every day. He believes his passion for psychiatry along with the relationships he's developed with his colleagues and mentors will carry him to be a lifelong learner and devoted psychiatrist for his future patients.
Meghan is a graduate of Lincoln Memorial University, DeBusk College of Osteopathic Medicine.
She received her Bachelor of Arts from the University of Denver in French and Biology with a concentration in Cognitive Neuroscience.
She is currently a chief resident at UACOM-Tucson in her final year of psychiatry training and will be starting a fellowship in Addiction Medicine at the University of Arizona, Tucson in July.
Her professional interests include physician mental health, adult consult liaison and addiction psychiatry.
In her personal time, she enjoys home design projects, spending time with family, learning about plants, and exploring new places.
Dr. Hintze is currently honeymooning in Japan! Congratulations!!
Danny is originally from Phoenix. Graduated from Brophy, ASU, and UA Tucson Medical School. His background is in economics, philosophy of science, and rational decision-making.
He was drawn to psychiatry because of the conceptual complexity and the profound impact even relatively simple pharmaceutical, medical, and psychotherapeutic interventions can have to empower patients and their families.
As a mentor, he wanted to recognize the many people within the Arizona Medical Community, particularly at UA Tucson, Valleywise, and within organized medicine who have worked to protect and promote medicine as a joyful, compassionate, and healing experience for patients and for all of us who help care for them.

ARIZONA PSYCHIATRIC SOCIETY past presidents

Otto L. Bendheim, M.D. 1960-1961Warren S. Williams, M.D. 1961-1963T. Richard Gregory, M.D. 1963-1964Boris Zemsky, M.D. 1964-1965 Hal J. Breen, M.D. 1965-1966Joseph M. Green, M.D. 1966-1967Irene M. Josselyn, M.D. 1967-1968Hubert R. Estes, M.D. 1968-1969Richard H. Bruner, M.D. 1969-1970Thomas F. Kruchek, M.D. 1970-1971David S. Burgoyne Sr., M.D. 1971-1972Marshall W. Jones, M.D. 1972-1973Harold D. Haeussler, M.D. 1973-1974William B. Haeussler, M.D. 1974-1975Edward S. Gelardin, M.D. 1975-1976Hugo L. Cozzi, M.D. 1976-1977Robert F. Meyer, M.D. 1977-1978James E. Campbell, M.D. 1978-1979Stuart M. Gould, M.D. 1979-1980Elliot M. Heiman, M.D. 1980-1981Stephen V. Shanfield, M.D. 1981-1982Jerry A. Biggs, M.D. 1982-1983Robert C. Shapiro, M.D. 1983-1984Dennis C. Westin, M.D. 1984-1985John H. Jarvis, M.D. 1985-1986James G. Hill, M.D. 1986-1987Robert P. Bevan, M.D. 1987-1988Eugene J. Kinder, M.D. 1988-1989 James M. Campbell, M.D. 1989-1990David S. Burgoyne II, M.D. 1990-1991
Stuart W. Hollingsworth, M.D. 1991-1992Kevin J. Leehey, M.D. 1992-1993Stephen S. Brockway, M.D. 1993-1994Michael H. Stumpf, M.D. 1994-1995Lauro Amezcua-Patino, M.D. 1995-1996David S. Burgoyne II, M.D. 1997-1998Glenn Lippman, M.D. 1998-1999Lisa Jones, M.D. 1999-2000David J. Coons, M.D. 2000-2001James M. Campbell, M.D. 2001-2002Bradley Johnson, M.D. 2002-2003David W. Leicken, M.D. 2003-2004Thomas N. Crumbley, M.D. 2004-2006Jeffrey L. Schwimmer, M.D., M.P.H. 2006-2007Stephen O. Morris, M.D. 2007-2008Jack L. Potts, M.D. 2008-2009Elizabeth A. Kohlhepp, M.D. 2009-2010Michael E. Brennan, M.D. 2010-2011Gretchen Alexander, M.D. 2011-2012Tariq M. Ghafoor, M.D. 2012-2013Joanna K. Kowalik, M.D., M.P.H., 2013-2014Payam M. Sadr, M.D., 2014-2015Roland Segal, M.D., 2015-2016Gurjot Marwah, M.D., 2016-2017Aaron Wilson, M.D., 2017-2018Mona Amini, M.D., 2018-2019 Don J. Fowls, M.D., 2019-2020 Jasleen Chhatwal, M.B.B.S., M.D., 2020-2022 Stephen Larry Mecham, DO, 2022-2023 Gagandeep Singh, MD, DFAPA 2023-2024
Main Menu
  • Home
  • About APS
  • APS News
  • Job Postings and Ads
  • Events and Education
  • 2023 Annual Meeting
  • Education-OUD
  • Education-On Demand
  • Mental Health Resources
Contact Information
Address: 2401 West Peoria Avenue, Suite 315 Phoenix, Arizona 85029
Phone: 602-909-4388
E-mail: admin@azpsych.org
Social
The Arizona Psychiatric Society is committed to ensuring the accessibility of its website to people with disabilities. If you have trouble accessing any of the Arizona Psychiatric Society's resources, please contact us at admin@azpsych.org for assistance Copyright © 2020 Network Solutions, LLC, A Web.com Company. All rights reserved.

We use cookies to enable essential functionality on our website, and analyze website traffic. By clicking Accept you consent to our use of cookies. Read about how we use cookies.

Your Cookie Settings

We use cookies to enable essential functionality on our website, and analyze website traffic. Read about how we use cookies.

Cookie Categories
Essential

These cookies are strictly necessary to provide you with services available through our websites. You cannot refuse these cookies without impacting how our websites function. You can block or delete them by changing your browser settings, as described under the heading "Managing cookies" in the Privacy and Cookies Policy.

Analytics

These cookies collect information that is used in aggregate form to help us understand how our websites are being used or how effective our marketing campaigns are.